학술논문
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Document Type
Article
Author
Source
In Journal of Thoracic Oncology April 2020 15(4):609-617
Subject
Language
ISSN
1556-0864